Research programme: cancer therapeutics - Bessor Pharma
Latest Information Update: 07 Sep 2016
At a glance
- Originator Bessor Pharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 07 Sep 2016 Preclinical trials in Solid tumours in USA (unspecified route) before September 2016